Atlas Bio is developing an AI foundation model that predicts drug efficacy and safety in virtual patients, potentially reducing years of clinical testing to weeks.
Atlas Bio has raised €11M across 1 funding round from 3 investors, most recently a Seed round in Oct 2026. Based in Basel, Switzerland; active in Healthtech. Data as of 27 Oct 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-10-27 | Seed | €11M |
| Creandum,First Momentum Ventures,Lea Partners |
| View deal → |
Global coverage: FundingData
